

Test requisition

Patient Information (Required)									
LAST NAME			FIRST NAME			MI	SUFFIX	DOB (MM/DD/YYYY)	BIOLOGICAL SEX <input type="checkbox"/> M <input type="checkbox"/> F
MEDICAL RECORD NUMBER					ASSOCIATED TEST ORDER NUMBER (OPTIONAL)				
STREET			APT/SUITE	CITY			STATE	ZIP CODE	
EMAIL					PHONE				
RACE <input type="checkbox"/> Asian <input type="checkbox"/> Black or African American <input type="checkbox"/> Native American <input type="checkbox"/> White <input type="checkbox"/> Other: _____							ETHNICITY <input type="checkbox"/> Hispanic/Latino <input type="checkbox"/> Not Hispanic/Latino <input type="checkbox"/> Unknown		

Ordering Physician Information (Required)				
INSTITUTION				
LAST NAME		FIRST NAME	MI	
NPI		EMAIL		
PHONE		FAX		
STREET	CITY	STATE	ZIP CODE	

Additional Provider (Send copy of reports)	
INSTITUTION	
NAME	EMAIL
PHONE	FAX

Pathologist Information (Required for tissue specimen)				
INSTITUTION				
LAST NAME		FIRST NAME	MI	
EMAIL		PHONE	FAX	
STREET	CITY	STATE	ZIP CODE	

Test(s) Requested (Required)	
<input type="checkbox"/> <b>ASPYRE CLINICAL TEST FOR LUNG</b> 11 genes, 114 targets ( <i>BRAF, EGFR, ERBB2, KRAS, RET, ROS, ALK, MET</i> Exon 14 skipping, <i>NTRK</i> 1, 2, & 3)	
<input type="checkbox"/> <b>Optional PD-L1 IHC Testing*</b> (Tissue ONLY; requires 4 additional slides) Please select ONE: <input type="checkbox"/> Dako 22C3 (cemiplimab-rwlc, pembrolizumab) <input type="checkbox"/> Ventana SP142 (atezolizumab) <input type="checkbox"/> Ventana SP263 (atezolizumab) <input type="checkbox"/> Dako 28-8 (nivolumab)	
<input type="checkbox"/> <b>Optional HER2 IHC Testing*</b> (Tissue ONLY; requires 3 additional slides) * PD-L1 and HER2 IHC performed and reported by Pathline LLC, NJ, CLIA #31D2050001	

Specimen Information (Required)	
SPECIMEN TYPE <input type="checkbox"/> FFPE Tissue Block <input type="checkbox"/> FFPE Tissue Slides (5 µm) Unstained* Block ID: _____ * Minimum 10 for Aspyre Clinical Test for Lung + 4 for PD-L1 OR + 3 for HER2 OR + 5 for PD-L1 and HER2	
<input type="checkbox"/> <b>Peripheral Whole Blood (2 PAXgene Tubes)</b>	
SPECIMEN SITE	COLLECTION DATE (MM/DD/YYYY)
RETURN BLOCK REQUESTED? <input type="checkbox"/> No <input type="checkbox"/> Yes (See reverse)	COLLECTION TIME

Patient Clinical History (Required)	
DIAGNOSIS <input type="checkbox"/> NSCLC <input type="checkbox"/> Other: _____	DISEASE STAGE
ATTACHMENTS <input type="checkbox"/> Recent Pathology/Cytology Reports <input type="checkbox"/> Test Results From Other Molecular Assays <input type="checkbox"/> Other Clinical Notes	

Billing Information (Required; attach copy of front and back of patient's insurance card)			
ICD-10 CODES _____			
PAYMENT TYPE <input type="checkbox"/> Insurance <input type="checkbox"/> Medicare <input type="checkbox"/> Hospital/Institution <input type="checkbox"/> Self-Pay		PATIENT STATUS <input type="checkbox"/> Hospital Inpatient <input type="checkbox"/> Hospital Outpatient <input type="checkbox"/> Non-Hospital Patient	
SUBSCRIBER LAST NAME		SUBSCRIBER FIRST NAME	DOB (MM/DD/YYYY)
PHONE		RELATIONSHIP TO INSURED <input type="checkbox"/> Self <input type="checkbox"/> Spouse <input type="checkbox"/> Child <input type="checkbox"/> Other: _____	
PRIMARY INSURANCE	POLICY #	GROUP #	PRIOR AUTHORIZATION #
SECONDARY INSURANCE	POLICY #	GROUP #	PRIOR AUTHORIZATION #

Treating Physician Consent/Certification of Medical Necessity (Required)
<p>My signature certifies that I have determined that the test(s) being ordered is medically necessary for the patient, certifies that the results of this test will inform the patient's ongoing treatment plan, and certifies that I am the patient's treating physician. I have explained to the patient the nature and purpose of the test(s) to be performed and have obtained the patient's informed consent and authorization, to the extent required under applicable federal and state law, to permit Biofidelity, or any laboratory with which Biofidelity has contracted, to (a) perform the test(s) specified herein, (b) analyze and report on other genomic information generated during the testing process or conduct additional analyses of the patient's sample for future diagnostic or monitoring use, (c) use results from test(s) specified herein for verification of test accuracy, (d) retain the test results and any biospecimens for an indefinite period for internal quality assurance/operations purposes, (e) de-identify any biospecimens and data in accordance with the HIPAA Privacy Rule and use and/or disclose such de-identified information and materials for future unspecified research, or other purposes, and (f) release the test results and related patient information to the patient's third-party payer as needed for reimbursement purposes.</p> <p>TREATING PHYSICIAN SIGNATURE: _____    NAME (PRINT): _____    DATE (MM/DD/YYYY): _____</p>

FFPE Block Return Information (Required if return block requested)				
OFFICE/PRACTICE			ATTN	
STREET		APT/SUITE	CITY	
STATE	ZIP CODE		EMAIL	PHONE

Relevant Clinical History (FOR BLOOD ONLY - All required for medical coverage determination)	
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is a tissue specimen from a recent procedure available?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is the tissue specimen insufficient for testing or tissue testing resulted as a Quantity Not Sufficient (QNS)?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is the patient medically unfit for invasive sampling?

Tumor Confirmation Testing
Tumor cellularity will be confirmed prior to running Aspyre Clinical Test for Lung for tissue specimens. Tumor confirmation consists of determination of specimen adequacy for testing and annotation of tumor section.

For Medicare Beneficiaries Only
A Medicare Advance Beneficiary Notice (ABN) may be provided to a Medicare patient if Medicare will likely not cover the testing service. This requisition form does not constitute an ABN.

About the Test
Aspyre Clinical Test for Lung evaluates comprehensive cancer care guideline-recommended DNA and RNA variants known to be actionable in non-small cell lung cancer (NSCLC). Targets include <i>BRAF</i> V600E (missense), <i>EGFR</i> exon 18 (missense), <i>EGFR</i> exon 19 (indels), <i>EGFR</i> exon 20 (missense, insertions & duplications), <i>EGFR</i> exon 21 (missense), <i>ERBB2</i> exon 17 (missense) and <i>ERBB2</i> exon 20 (insertions), <i>KRAS</i> exon 2 and <i>KRAS</i> exon 3 (missense), <i>ALK</i> (fusions), <i>ROS1</i> (fusions), <i>RET</i> (fusions), <i>MET</i> exon 14 skipping, and <i>NTRK</i> 1/2/3 (fusions). DNA and RNA are extracted from formalin fixed paraffin embedded (FFPE) tissue or peripheral whole blood. Targets are amplified by multiplex (RT) PCR, and variants are detected using ASPYRE (Allele-Specific PYrophosphorolysis REaction) detection chemistry with read out on a real-time PCR instrument. For more information, visit: <a href="http://www.biofidelity.com">www.biofidelity.com</a> .